Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD8+ T cell epigenetic program is the regulatory framework of chromatin modifications and DNA methylation that dictates the functional state of cytotoxic T lymphocytes. During chronic antigen exposure, such as in cancer or chronic viral infections, CD8+ T cells transition from an effector state to an "exhausted" state, a process driven by a stable and distinct epigenetic landscape [3, 4]. This program is characterized by the closing of chromatin at effector gene loci (e.g., IFNG, GZMB) and the opening of regions associated with inhibitory receptors like PD-1 and transcription factors like TOX [1, 2]. Therapeutic intervention seeks to modulate this program using small molecule inhibitors of epigenetic enzymes, such as DNA methyltransferases (DNMTs) or histone methyltransferases (e.g., EZH2), to "reprogram" exhausted cells back toward a functional effector or memory-like phenotype [2, 5]. Successfully targeting this program is a key strategy for overcoming resistance to checkpoint blockade and improving the efficacy of adoptive cell therapies. Key molecular drivers of this program include the HMG-box transcription factor TOX and the nuclear receptor NR4A, which coordinate with epigenetic modifiers to enforce a state of hyporesponsiveness [1]. Unlike transient functional changes, the epigenetic program represents a "molecular scar" that limits the long-term durability of current immunotherapies [3]. Research into this program aims to identify specific enzymatic targets that can be safely inhibited to enhance the metabolic and functional fitness of T cells in the tumor microenvironment. Sources: [1] Khan, O., et al. (2019). TOX is a critical regulator of T cell exhaustion. Nature. [2] Ghoneim, H. E., et al. (2017). De Novo Epigenetic Programs Inhibit T Cell Pluripotency and Restrict Responses to Checkpoint Blockade. Cell. [3] Pauken, K. E., et al. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. [4] Zebley, C. C., et al. (2020). The epigenetic landscape of T cell exhaustion. JCI Insight. [5] Belk, J. A., et al. (2022). Genome-wide CRISPR screens of T cell cytotoxicity reveal novel epigenetic regulators. Nature.
Epigenetic reprogramming via inhibition of DNA methyltransferases (DNMTs), histone deacetylases (HDACs), or histone methyltransferases (e.g., EZH2) to reverse exhaustion-associated chromatin states and enhance T cell persistence and effector function.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD8+ T cell epigenetic program.